Access Bio signs ₩5.0bn supply contract with P&G for home tests
Access Bio filed a supply contract with The Procter & Gamble Manufacturing Company for the Flu A + Flu B + COVID-19 Combo Home Test, with a contract amount of ₩5.0bn. The filing reports this as 15.9% of revenue, and the contract period runs from Oct 15, 2026 to Oct 14, 2027.
Key facts
| Contract name | Flu A + Flu B + COVID-19 Combo Home Test supply contract |
|---|---|
| Counterparty | The Procter & Gamble Manufacturing Company |
| Contract amount | ₩5.0bn |
| % of revenue (as reported) | 15.9% |
| Period start | Oct 15, 2026 |
| Period end | Oct 14, 2027 |
Comparison
| Amount as % of FY2025 revenue (calculated) | 22597.4% |
|---|---|
| Revenue 2025 | ₩22m |
| Revenue 2024 | ₩82m |
| Revenue 2023 | ₩267m |
Context
By our calculation, the contract amount is 22597.4% of FY2025 revenue.
Key metrics
Supply contracts
| Supply contracts, last 12 months | ₩5.0bn |
|---|---|
| Supply contracts vs prior-year revenue | 22597.4% |
| Contracts without a KRW amount | 0 contracts without a KRW amount excluded |
Source: DART (Financial Supervisory Service) · Original filing on DART ↗